At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies.
Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, bone, and blood vessels. Based on this expertise, we have built a robust pipeline of protein therapeutics targeted to key mechanisms underlying blood diseases and cancer.
Since our founding in 2004, Acceleron has brought four distinct, internally-discovered, developed and manufactured products into clinical trials, and has established collaborations with leading biopharmaceutical companies and research institutions to bring these products to the patients who need them.
Closing share price